[1] World Health Organization. Hepatitis E, https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-e
[2] Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med, 2008,358(8):811-817.
[3] Dalton HR, Bendall RP, Keane FE, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med, 2009,361(10):1025-1027.
[4] Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology, 2011,140(5):1481-1489.
[5] Buescher G, Ozga AK, Lorenz E, et al. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. Liver Int, 2021, 41(3):449-455.
[6] Koning L, Charlton MR, Pas SD, et al. Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis, 2015,15:371.
[7] Lampejo T, Curtis C, Ijaz S, et al. Nosocomial transmission of hepatitis E virus and development of chronic infection: The wider impact of COVID-19. J Clin Virol, 2022,148:105083.
[8] Geng Y, Zhang H, Huang W, et al. Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepat Mon, 2014,14(1):e15618.
[9] Abravanel F, Lhomme S, El Costa H, et al. Rabbit Hepatitis E Virus Infections in Humans, France. Emerg Infect Dis, 2017,23(7):1191-1193.
[10] Sahli R, Fraga M, Semela D, et al. Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland. J Hepatol, 2019,70(5):1023-1025.
[11] Sridhar S, Yip CC, Wu S, et al. Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis. Hepatology, 2021, 73(1):10-22.
[12] Costafreda MI, Sauleda S, Rico A, et al. Detection of non-enveloped hepatitis E virus in plasma of infected blood donors. J Infect Dis, 2021 4:jiab589.
[13] Matsubayashi K, Nagaoka Y, Sakata H, et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion, 2004,44(6):934-940.
[14] Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet, 2014,384(9956):1766-1773.
[15] Mansuy JM, Gallian P, Dimeglio C, et al. A nationwide survey of hepatitis E viral infection in French blood donors. Hepatology, 2016, 63(4):1145-1154.
[16] Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet, 2010,376(9744):895-902.
[17] Zaman K, Dudman S, Stene-Johansen K, et al. HEV study protocol : design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh. BMJ Open, 2020,10(1):e033702.
[18] Borentain P, Colson P, Bolon E, et al. Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis. Hepatology, 2018,67(1):446-448.
[19] Zhou X, Huang F, Xu L, et al. Hepatitis E Virus Infects Neurons and Brains. J Infect Dis, 2017,215(8):1197-1206.
[20] Tian J, Shi R, Liu T, et al. Brain Infection by Hepatitis E Virus Probably via Damage of the Blood-Brain Barrier Due to Alterations of Tight Junction Proteins. Front Cell Infect Microbiol, 2019,9:52.
[21] Horvatits T, Wi?mann JE, Johne R, et al. Hepatitis E virus persists in the ejaculate of chronically infected men. J Hepatol, 2021,75(1):55-63.
[22] Bremer W, Blasczyk H, Yin X, et al. Resolution of hepatitis E virus infection in CD8+ T cell-depleted rhesus macaques. J Hepatol, 2021,75(3):557-564.
[23] Senosiain C, González-Tallón A A, López-Sanromán A, et al. Hepatitis E seroprevalence in inflammatory bowel disease. Gastroenterol Hepatol, 2016,39(3):185-190.
[24] Pischke S, Stiefel P, Franz B, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant,2012,12(11):3128-3133.
[25] Cornberg M, Pischke S, Müller T, et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. J Hepatol, 2020,73(3):696-699.
[26] Li Y, Yu P, Kessler AL, et al. Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology, 2022,75(1):196-212.
[27] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol, 2018,68(6):1256-1271.
[28] Kamar N, Abravanel F, Behrendt P, et al. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. Clin Infect Dis, 2020,71(5):1204-1211.
[29] Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med, 2014,370(12):1111-1120.
[30] Kamar N, Chatelut E, Manolis E, et al. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis, 2004,43(1):140-146.
[31] Todt D, Gisa A, Radonic A, et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut, 2016,65(10):1733-1743.
[32] Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis, 2010,50(5):e30-33.
[33] Sridhar S, Chan JFW, Yap DYH, et al. Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong. J Viral Hepat, 2018 Feb,25(2):209-213. |
